TXG Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own TXG shares is 377, representing 98.01% of the company's common stock.

INVESCO LTD., in the last quarter, reduced its stake in TXG by -96.41% restricting it's holding to 83.81 thousand shares of worth nearly $3.15M. JPMORGAN CHASE & CO also lessened -94.62% of the TXG shares from its portfolio, reducing its holding to 79.43 thousand shares of worth $2.98M. SANDS CAPITAL MANAGEMENT, LLC also shunned TXG shares holding by -5.77% last quarter which brought its holding to 3.38 million shares worth $126.97M.

As per its latest 13F filing, ARK INVESTMENT MANAGEMENT LLC increased its stake in TXG by 55.49% in the last quarter. The institutional holder raised its holding to 6.28 million shares having worth more than $235.83M. SUSQUEHANNA INTERNATIONAL GROUP, LLP also added 100% more shares of TXG to its portfolio, raising its holding to 105.8 thousand shares of worth $3.97M. SEVEN EIGHT CAPITAL, LP also increased its TXG shares holding by 100% which brought its holding to 99.88 thousand shares worth $3.75M.

The insider with the most stakes in TXG is Saxonov Serge , Chief Executive Officer at the company. Additionally, TXG stock is highly held by See Remarks Hindson Benjamin J. and director STUELPNAGEL JOHN R among others.

Company executives, directors, and other insiders own 2.16% percent of 10x Genomics, Inc.'s stock. Within the last six months, there have been 5 transaction(s) in which TXG insiders have sold stock, totaling 26.56K shares. Insiders that have sold shares include SAXONOV SERGE, HINDSON BENJAMIN J., and MCANEAR JUSTIN J..

There have been 0 transaction(s) during the past 6-months in which 10x Genomics, Inc. insiders have bought stock, totalling 0 shares

Around 2.58M 10x Genomics, Inc. shares are held by insiders, which represents about 2.16% of TXG stock.

TXG Chief Executive Officer, Saxonov Serge holds the largest portfolio of the company's shares. TXG shares owned by Saxonov total nearly 872.57 thousand.

ARK INVESTMENT MANAGEMENT LLC is the largest institutional owner in TXG which holds 6.28 million shares worth $235.83M or 5.26% of the total TXG shares outstanding followed by SUSQUEHANNA INTERNATIONAL GROUP, LLP with ownership of 105.8 thousand shares representing 0.09% of the TXG ownership. SEVEN EIGHT CAPITAL, LP is the third largest stakeholder with 99.88 thousand shares or 0.09% of the ownership worth more than $3.75M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the TXG is concerned, it is a stock which is optionable.

Number of TXG shares short is 6.60M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 107.00M shares of TXG are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, TXG has 104.96M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for TXG is 4.05.